NEW YORK & PITTSBURGH--(BUSINESS WIRE)--RenovaCare, Inc. (OTCQB:RCAR), today announced a partnership to validate the science behind its groundbreaking technology for treatments of wounds, burns and other skin defects. The company’s research partner is Berlin-Brandenburg Center for Regenerative Therapies (BCRT), a translational research center at Charité - Universitätsmedizin Berlin, one of the world’s largest university hospitals.
“We plan to assess all aspects of the company’s technology as it is related to the tissue’s wound-healing function and the characteristics of the treated site.”
The BCRT focuses on enhancing endogenous regeneration by cells, biomaterials, and factors, which can be used to develop and implement innovative therapies and products. RenovaCare, Inc. is the developer of the patented CellMist™ and SkinGun™ technologies for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing.
“This collaboration with a globally-renowned institution is a huge step forward for RenovaCare as we set out to achieve third party validation of the science behind the promise of our CellMist™ and SkinGun™ technologies,” said Thomas Bold, President and CEO of RenovaCare, Inc. “We are honored to be working with such committed researchers known for partnering with innovative, world-class companies whose mission is to make peoples’ lives better.”
“We are very excited to be working with RenovaCare to advance the treatment of burns, and this project underscores the new treatments for severely burned patients and those with myriad skin conditions,” said Dr. Katrin Zeilinger, Project Leader for BCRT. “We plan to assess all aspects of the company’s technology as it is related to the tissue’s wound-healing function and the characteristics of the treated site.”
The objective of today’s announced research partnership is to evaluate protocols, methods, and outcomes related to the use of the RenovaCare proprietary SkinGun™. This includes better understanding the ability of delicate stem cells to survive and grow after being gently sprayed through SkinGun™ on to targeted body sites. Survival of these cells is vital to wound healing and recovery.
According to RenovaCare engineers, the company’s proprietary SkinGun™ spray device is the world’s most advanced technology of its kind, using an ultra-gentle non-turbulent air stream to spray the cells onto wounds. This is a marked improvement over pump spray devices, which create high-pressure forces behind a narrow aperture, exposing fragile cells to thrashing that is more likely to cause damage.
Scientists at BCRT will also study various additional features and behaviors related to skin stem cells and their ability to replicate and grow, for wound healing.
About Charité – Universitätsmedizin Berlin
With a total of 3,001 beds, Charité – Universitätsmedizin Berlin is one of the largest university hospitals in Europe. Charité spans four campuses and comprises approximately 100 Departments and Institutes. The areas of research, teaching, and health care delivery are intricately linked, resulting in a working relationship that is characterized by interdisciplinary cooperation. With approximately 7,000 future physicians and dentists currently enrolled in degree courses, Charité is one of the largest medical faculties in Germany. For additional information, please visit: http://www.charite.de/en/.
About RenovaCare
RenovaCare, Inc. is developing first-of-their-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. Its initial product under development targets the body’s largest organ, the skin. The company’s flagship technology, the CellMist™ System, uses its patented SkinGun™ to spray a liquid suspension of a patient’s stem cells – the CellMist™ Solution – onto wounds. RenovaCare is developing its CellMist™ System as a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars. In the US alone, this $45 billion market is greater than the spending on high-blood pressure management, cholesterol treatments, and back pain therapeutics.
The statements in this press release have not been evaluated by the U.S. Food and Drug Administration (FDA). RenovaCare products are not approved for sale in the United States.
For additional information, please call Drew Danielson at: 888-398-0202 or visit: http://renovacareinc.com.
To receive future press releases via email, please visit: http://renovacareinc.com/investors/register/.
Follow us on Twitter https://twitter.com/Renovacare_inc or follow us on Facebook https://www.facebook.com/renovacarercar.
For answers to frequently asked questions, please visit our FAQ’s page: http://renovacareinc.com/investors/faqs/.
Social Media Disclaimer
Investors and others should note that we announce material financial information to our investors using SEC filings and press releases. We use our website and social media to communicate with our subscribers, shareholders and the public about the company, RenovaCare, Inc. development, and other corporate matters that are in the public domain. At this time, the company will not post information on social media that could be deemed to be material information unless that information was distributed to public distribution channels first. We encourage investors, the media, and others interested in the company to review the information we post on the company’s website and the social media channels listed below:
* This list may be updated from time to time.
Legal Notice Regarding Forward-Looking Statements
No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although RenovaCare, Inc. (the “Company”) believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: the timing and success of clinical and preclinical studies of product candidates, the potential timing and success of the Company’s product programs through their individual product development and regulatory approval processes, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, obsolescence of the Company’s technologies, technical problems with the Company’s research, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company’s operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company’s ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, and other risks. There can be no assurance that further research and development will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that the Company will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Contacts
TrendLogic
Dwain Schenck, 800-992-6299
dwain@trendlogicpr.com
Help employers find you! Check out all the jobs and post your resume.
